|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's range||3.6100 - 4.0000|
|52-week range||3.4100 - 27.0000|
|Beta (5Y monthly)||1.51|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.00|
Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021
Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces an increase in enrollment in its pivotal clinical trial to evaluate the safety and effectiveness of the DABRA excimer laser system as an atherectomy device for the treatment of peripheral arterial disease (PAD). A total of 42 subjects have been enrolled as of April 19, 2021.
Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three and 12 months ended December 31, 2020 and provides a business update.